Eris Lifesciences Reports Strong Financial Growth Amid Rising Interest Expenses

Eris Lifesciences, a midcap player in the Pharmaceuticals and Biotechnology sector, has recently undergone a financial trend adjustment reflecting its robust performance in the quarter ending March 2025. The company reported a significant increase in key financial metrics, showcasing its operational strength.
Notably, the profit before tax (PBT) less other income surged to Rs 120.92 crore, marking a remarkable growth of 96.30%. The operating profit to interest ratio reached an impressive 4.65 times, indicating strong profitability relative to interest expenses. Additionally, net sales climbed to Rs 705.30 crore, reflecting a growth rate of 28.02%. The operating profit to net sales ratio also stood at a high of 35.78%, while the profit after tax (PAT) peaked at Rs 93.84 crore, translating to an earnings per share (EPS) of Rs 6.89.

However, the company faced challenges with interest expenses, which grew to Rs 170.92 crore, up by 53.26%.

In terms of market performance, Eris Lifesciences has outperformed the Sensex over various time frames, including a notable 59.94% return over the past year compared to the Sensex's 10.88%. This trend highlights the company's strong market position and resilience in a competitive landscape.